Preoperative Evaluation of Parkinson’s Disease

Bianca C. Woodruff 1, David Garcia 1, Shobhana Chaudhari 2

1. Anesthesiology, Metropolitan Hospital Center, New York, USA 2. Geriatrics, Metropolitan Hospital Center, New York, USA

Corresponding author: Bianca C. Woodruff, biancawoodruff75@gmail.com

Abstract

Parkinson’s disease (PD) is a common disease of older adults. It presents a unique set of anesthetic challenges. With increasing life expectancy and the rapid growth of oldest-old patients, it is now more likely for anesthesiologists to encounter older patients with PD. Due to polypharmacy in the older adults with PD potential for drug interactions during and after surgery needs to be considered. More data from prospective, multicenter trials about short- and long-term outcomes of anesthesia in PD patients are needed.

Introduction

Parkinson’s disease (PD) is one of the common neurological diseases in older adults. It affects approximately one million individuals in the United States and 10 million individuals worldwide [1]. It is a progressive neurodegenerative disease of the central nervous system caused by the loss of dopaminergic neurons in the basal ganglia of the brain and is characterized by a classical triad of resting tremor, muscle rigidity, and bradykinesia [2]. PD is an important cause of perioperative morbidity whereby complications commonly arise from the impact of the disease on the respiratory, cardiovascular, gastrointestinal, urological, and neurological systems. The rates of postoperative aspiration pneumonia (due to laryngeal/pharyngeal muscle dyskinesia), post-extubation laryngospasm, orthostatic dysregulation, arhythmias, bacterial infections, urinary tract infections, sialorrhea, gastroesophageal reflux disease (GERD), gastroparesis with chronic constipation, falls, prolonged hospital stay, postoperative hallucinations and delirium, cognitive impairments, and greater need for post-hospitalization rehabilitation are significantly increased in this population [3]. Polypharmacy in older PD patients can lead to potential interactions with anesthetic drugs. Here we present a challenging case of an older adult with PD who needed the preoperative evaluation.

Case Presentation

An 80-year-old female with a medical history of PD, history of multiple intracranial aneurysms with multiple embolizations secondary to subarachnoid bleed complicated by left carotid-cavernous fistula formation, hypertension, systolic chronic heart failure with reduced ejection fraction, chronic kidney disease stage 3, and left bundle branch block presented at the geriatric clinic for a preoperative evaluation. An elective cerebral angiography and possible transvenous embolization of the left carotid-cavernous fistula was planned to treat the patient’s decreasing vision, diplopia, and headache. The past surgical history was significant for bilateral cataract extraction, cholecystectomy, and multiple cerebral angiograms with embolization of the right ophthalmic artery aneurysm.

Home medication included three medications for PD as selegiline 5 mg BID, rotigotine transdermal patch 2 mg/24 h, and trihexyphenidil 2 mg TID due to left-hand tremors and rigidity progression. Additionally, she was on losinopril 40 mg, calcium carbonate + Vitamin D 600/400 mg BID, Vitamin B12 1 mg, acetaminophen pro re nata (PRN) 500 mg, aspirin 81 mg, and clopidogrel 75 mg. The patient was ambulatory without an assistive device, with trouble initiating movement, a typical shuffling gait, and reported an exercise tolerance of more than 15 blocks.

On physical examination, she was awake, alert, and oriented x 3 and had “pill rolling” tremor and cogwheel rigidity of the left upper extremity. Her vital signs were blood pressure (BP) 142/64, heart rate (HR) 93 beats/min, respiratory rate (RR) 18 breaths/min, afebrile, and O2 saturation 98% on room air. The remaining physical review was unremarkable. Her laboratory examination showed chronic normocytic/normochromic anemia with a normal anemia workup. Her electrocardiogram was significant for a known left bundle branch block. Her last echocardiogram confirmed a left ventricular ejection fraction of 40%-45%.

The revised cardiac risk index for the patient was low to intermediate for a high-risk procedure. The patient was advised to hold selegiline on the day of the procedure due to possible interactions with intra-operative medications and the elevated risk of precipitating serotonin syndrome. She was recommended to take all other medications early in the morning and to resume her anti-Parkinson medication as soon as possible after the procedure. The patient underwent the proposed procedure under general anesthesia, was extubated...
in the operating room, and transferred to the ICU for close monitoring. The procedure was a successful 
surpass streamline flow diverter insertion of a complex one centimeter left cavernous segment aneurysm, as 
well as a three-millimeter, left ophthalmic artery aneurysm along a dysmorphic segment. The surpass 
streamline flow diverter is a cobalt chromium and platinum tungsten braided, self-expandable tube. The 
procedure was complicated by rupture of the cavernous aneurysm with cavernous carotid fistula draining 
towards the pterygoid veins, which was treated with placement of a second surpass streamline flow diverter. 
During the postoperative management, the patient maintained her baseline physical exam and mental status 
presented with left eye pain and mild hypertension that was treated successfully with dexamethasone and 
labetalol. The PD medications were restarted during the ICU stay, without any adverse effects. On a 
postoperative day five, the patient was discharged from the hospital with dexamethasone tapering, aspirin 
325 mg, clopidogrel 75 mg, and close follow-up visits with the Geriatrics and Neurology department.

Discussion

Antiparkinsonian medications should not be withheld. A missed dose can lead to increased rigidity, loss of 
balance, agitation, and confusion. If PD medication is withheld for too long, neuroleptic malignant 
syndrome or parkinsonism-hyperpyrexia syndrome can develop. Thus, to avoid symptom exacerbation and 
other adverse effects the usual drug regimen should be continued until just before the induction of 
anesthesia, except in patients undergoing surgery for deep brain stimulators [4]. In that case, medications 
should be withheld in the morning only. Levodopa’s half-life is only one to three hours. Enteral 
administration is preferred due to the fact that IV administration of levodopa increases the risk of 
interactions with anesthetic agents and can cause arrhythmias and hypertension via its metabolite, 
dopamine. If postoperative enteral administration is impossible, a transdermal application of rotigotin 
should be used.

Furthermore, PD patients should be the first surgery cases of the day [5]. Placing these patients first, and 
ensuring they stay on their scheduled PD medications during their nil per os (NPO) status, is important. If 
scheduling as the first case is not possible, PD patients should be allowed to take their PD medications with 
a sip of water during the day of surgery.

Patients on levodopa treatment can have severe nausea and vomiting, intensified by opioids given during 
general anesthesia. They are prone to dehydration and hypovolemia, can develop orthostatic hypotension 
and/or arrhythmia, and are susceptible to postoperative delirium with visual hallucinations, which can also 
be intensified by intraoperative opioids and benzodiazepines. Adequate fluid management during the 
perioperative period is crucial to prevent orthostatic hypotension.

Depression is a common neuropsychiatric manifestation of PD, and selective serotonin reuptake inhibitors 
(SSRI) medications prescribed for many patients with PD to treat depression can interact with serotonergic 
medications given during the perioperative period (like tramadol, meperidine, fentanyl, ondansetron, and 
granisetron). Such drug-drug interaction increases the risk for potentially fatal serotonin syndrome and 
should be avoided.

Acetylcholinesterase inhibitors (rivastigmine, donepezil, and galantamine), commonly prescribed to treat 
PD dementia, have been associated with a prolonged effect of succinylcholine (up to 50 min) and increased 
resistance to non-depolarizing neuromuscular blocking drugs.

For evaluation of the anesthetic plan, the following points have to be considered: thiopental decreases the 
release of dopamine in the striatal synaptosome. One case of peri- and postoperative rigor with 
parkinsonian episodes seen after induction with 575 mg thiopental has been described [6]. Etomidate can 
cause myoclonus that can be decreased with the simultaneous use of benzodiazepines [3]. Ketamine can 
produce intraoperative unprecented BP responses and postoperative hallucinations and is, therefore, 
theoretically contraindicated. However, it can also provide patient comfort and resolution of dyskinesia via 
its N-methyl-D-aspartate (NMDA) antagonist properties. At low doses (0.1-0.5 mg/kg IV) ketamine is a safe 
and useful temporary adjunct to long-term treatment when dopamine medications are missed within the 
perioperative setting [7]. Propofol, the most commonly used anesthetic drug, has been reported to induce 
dyskinesia. Propofol increases striatal levels of gamma-aminobutyric acid (GABA), and increased 
concentrations of GABA receptors have been observed postmortem in the globus pallidus internus of 
parkinsonian patients prone to dyskinesia, indicating that these patients may be more sensitive to the effects 
of GABA than patients without PD [8]. Research has found that propofol inhibits neuronal activity in the 
subthalamic nucleus, and that lesion of the subthalamic nucleus can result in disorders of excessive 
movement such as ballism and chorea. Nonetheless, propofol is often used in patients with PD undergoing 
surgery because of its favorable anesthetic and antiemetic properties. However, clinicians should remain 
aware of the increased risk for propofol-induced dyskinesia in this group, especially in those with advanced 
disease. As described in a report published in 2006, dexametomidine was found to manage propofol- 
induced dyskinesia successfully in a patient with PD undergoing deep brain stimulator 
placement [9]. Regional anesthesia (RA) might be preferred due to its advantages: does not mask a PD 
exacerbation, enables intraoperative monitoring of parkinsonian symptoms, allows earlier return to 
postoperative oral intake, reduces the use of systemic opioids, does not require anticholinergic reversal 
agents, and has a lower risk of aspiration. Low-dose midazolam in combination with low-dose remifentanil
infusion could be used. However, the disadvantages of RA in PD patients must also be considered. The PD tremor can interfere not only with the monitoring device but might also make surgery impossible. Available clinical evidence does not show persisting cognitive decline in PD patients after repeated general anesthesia [10]. Inhalational anesthetics, which have a complex impact on the brain, can lead to an increase of extracellular dopamine via inhibition of synaptic reuptake and increased release of dopamine [11-12]. Neuronal connections of dopamine are generally safe to use in PD. The ideal agent is rocuronium because of its antidote sugammadex. Neostigmine should be used with caution due to its thickening effect on airway secretions. Opioids are safe in PD except for meperidine and tramadol due to the increased risk of precipitating serotonin syndrome. Some cases of increased muscle rigidity in PD patients given high opioid doses have been published. Sialorrhea can complicate airway management but this can be reduced with glycopyrrolate. Due to the increased prevalence of gastroparesis and GERD in PD patients, a rapid sequence induction is preferable. Centrally acting anticholinergic (atropine) can precipitate a central anticholinergic syndrome with confusion, somnolence, and restlessness. Glycopyrrolate is a safe peripherally acting alternative. Antimuscarinic drugs like neostigmine increase the viscosity of saliva and impair swallowing, thereby, increasing the risk of postoperative bronchospasm in patients with PD who have obstructive dysfunction due to parasympathetic overactivity. For postoperative nausea and vomiting, prophylaxis and treatment should be approached with caution. Consider total IV anesthesia agents, such as propofol and dexmedetomidine, which have opioid-sparing effects. Dexamethasone and serotonin antagonists are good agents for prophylaxis. Phenothiazines should be avoided because they may lead to Parkinson’s exacerbation.

Oral PD medication should be restarted after surgery as soon as possible, best case in the evening of the day of surgery, as severe akinesia, can have many negative perioperative effects. Levodopa can be administered via nasogastric (NG) tube. Rectal application is not recommended due to levodopa’s resorption in the proximal jejunum [13]. In case the enteral application is not possible, alternative treatments can be used: amantadine sulfate (200 mg IV once daily), apomorphine [1-2 mg subcutaneous (SC), half life is only 30 min, continuous SC application recommended], and rotigotine (transdermal patch 4 mg/24 h) [14]. Early rehabilitation with early postoperative mobilization is strongly recommended.

Postoperative delirium is particularly common and challenging in PD. With rates as high as 60%, postoperative delirium is best managed by non-pharmacological methods like reorientation (talking to the patient and explaining time, location, and your role) and providing a suitable care environment [15]. Drugs that precipitate or exacerbate PD like metoclopramide, phenothiazine (promethazine, prochlorperazine), butyrophenones (haloperidol, droperidol), or atypical anti-psychotics should be withheld prior to surgery (Table 1). Furthermore, opioids such as meperidine or tramadol should be discontinued prior to their procedure due to their interaction with PD medications (like monoamine oxidase B inhibitor, selegiline) and their risk of precipitating a serotonin syndrome.

### TABLE 1: Drugs that precipitate or exacerbate PD.

| Drugs that precipitate or exacerbate PD |
|----------------------------------------|
| Antiemetics                            |
| Metoclopramide                         |
| Typical antipsychotics                 |
| Chlorpromazine, prochlorperazine, perphenazine, fluphenazine, promethazine, haloperidol, droperidol, pimozide, sulphpride |
| Atypical antipsychotics                |
| Risperidone, olanzapine, ziprasidone, aripiprazole |

**Conclusions**

Polypharmacy, in older PD patients, can lead to potential drug interactions with anesthetic drugs and techniques. This article highlights the importance of preoperative evaluation of an older PD patient. Unfortunately, much of the evidence about the safety of various anesthetic drugs or techniques used in PD is based on single case reports or small case series. More data from prospective, multicenter trials about the short- and long-term consequences of general and regional anesthesia in older patients with PD are needed.

### Additional Information

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services**
info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Parkinson’s Foundation. (2018). Accessed: January 22, 2018: http://www.parkinson.org/Understanding-Parkinsons/Causes-and-Statistics/Statistics.
2. DeLong MR, Juncos JL: Parkinson’s disease and other movement disorders. Harrison’s Principles of Internal Medicine, 17th ed. Kasper DL, Fauci AS, Jameson JL (ed): McGraw Hill Medical Publishers, New York; 2008. 2406-2417.
3. Wüllner U, Standop J, Kaut O, Coenen V, Kalenka A, Wappler F: [Parkinson’s disease. Perioperative management and anesthetics]. Anaesthesist. 2012, 61:97-105. 10.1007/s00101-012-1992-6
4. How should Parkinson’s disease be managed perioperatively? . (2010). Accessed: June 12, 2021: https://www.the-hospitalist.org/hospitalist/article/124294/how-should-parkinsons-disease-be-managed-perioperatively.
5. The Michael J Fox Foundation . (2019). Accessed: June 12, 2021: https://www.michaeljfox.org/news/ask-md-having-surgery-when-you-have-parkinsons.
6. Muravchick S, Smith DS: Parkinsonian symptoms during emergence from general anestheis. Anesthesiology. 1995, 82:305-307. 10.1097/00000542-199501000-00039
7. Wright JJ, Goodnight PD, McEvoy MD: The utility of ketamine for the preoperative management of a patient with Parkinson’s disease. Anesth Analg. 2009, 108:980-982. 10.1213/ane.0b013e3181924025
8. Rodriguez T. Anesthesia in Parkinson disease requires cautious care . (2019): https://www.neurologyadvisor.com/topics/movement-disorders/anesthesia-in-parkinson-disease-requires-cautious-care/
9. Deogaonkar A, Deogaonkar M, Lee JY, Ebrahim Z, Schubert A: Propofol-induced dyskinesias controlled with dexmedetomidine during deep brain stimulation surgery. Anesthesiology. 2006, 104:1337-1359. 10.1097/00000542-200606000-00029
10. Avidan MS, Evers AS: Review of clinical evidence for persistent cognitive decline or incident dementia attributable to surgery or general anesthesia. J Alzheimers Dis. 2011, 24:201-216. 10.3233/JAD-2011-101680
11. el-Maghrabi EA, Eckenhoff RG: Inhibition of dopamine transport in rat brain synaptosomes by volatile anesthetics. Anesthesiology. 1995, 78:750-756. 10.1097/00000542-199504000-00019
12. Mantz J, Varlet C, Lecharny JB, Henzel D, Lenot P, Desmonts JM: Effects of volatile anesthetics, thiopental, and ketamine on spontaneous and depolarization-evoked dopamine release from striatal synaptosomes in the rat. Anesthesiology. 1994, 80:552-563. 10.1097/00000542-199402000-00015
13. Eissler T, Eng N, Plotkin C, Calne DB: Absorption of levodopa after rectal administration. Neurology. 1981, 31:215-217. 10.1212/wnl.31.2.215
14. Frampton JE: Rotigotine transdermal patch: a review in Parkinson’s disease . CNS Drugs. 2019, 33:707-718. 10.1007/s40263-019-00646-y
15. Pepper PV, Goldstein MK: Postoperative complications in Parkinson’s disease . J Am Geriatr Soc. 1999, 47:967-972. 10.1111/j.1532-5415.1999.tb01292.x